Guild Investment Management Inc. Sells 90 Shares of Eli Lilly and Company $LLY

Guild Investment Management Inc. decreased its position in Eli Lilly and Company (NYSE:LLY) by 2.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 3,151 shares of the company’s stock after selling 90 shares during the quarter. Eli Lilly and Company comprises approximately 2.1% of Guild Investment Management Inc.’s portfolio, making the stock its 21st largest holding. Guild Investment Management Inc.’s holdings in Eli Lilly and Company were worth $2,456,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Precedent Wealth Partners LLC grew its position in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after buying an additional 39 shares during the period. Capital Advisors Inc. OK grew its position in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares during the period. Family CFO Inc bought a new position in Eli Lilly and Company during the second quarter valued at about $54,000. Duquesne Family Office LLC grew its position in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the period. Finally, Corient IA LLC bought a new position in Eli Lilly and Company during the first quarter valued at about $570,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on LLY. Cantor Fitzgerald reduced their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Morgan Stanley dropped their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $943.00.

Eli Lilly and Company Trading Up 0.2%

Shares of Eli Lilly and Company stock opened at $845.55 on Thursday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a market cap of $800.28 billion, a price-to-earnings ratio of 55.26, a PEG ratio of 1.18 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company’s 50-day moving average price is $738.69 and its 200-day moving average price is $766.57.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm posted $3.92 earnings per share. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.